Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India

Introduction  Nivolumab monotherapy is approved for the treatment of metastatic renal cell carcinoma (mRCC) patients who have progressed on prior therapies based on the pivotal Checkmate-025 trial. There is limited literature on the efficacy and safety profile of usage of nivolumab in the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Rauthan, Amit, Murthy, Nitin Yashas, Patil, Poonam, Nigade, Gaurav, Somashekhar, SP, Zaveri, Shabber S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718606/
https://www.ncbi.nlm.nih.gov/pubmed/36466979
http://dx.doi.org/10.1055/s-0041-1740373

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718606/
https://www.ncbi.nlm.nih.gov/pubmed/36466979
http://dx.doi.org/10.1055/s-0041-1740373

Ejemplares similares